Adrenal Insufficiency Screening and Management in Patients on Prednisolone

Pharmacokinetics and Biological Effects

• The biological effects of prednisolone on HPA axis suppression persist much longer than the drug's presence in circulation, with a plasma half-life of 2-4 hours 1, 2

Evidence-Based Testing Protocol

• The American College of Physicians recommends waiting 48 hours after stopping prednisolone before performing the cosyntropin stimulation test to allow for accurate cortisol measurement 2, 3
• A peak cortisol level of less than 500 nmol/L at 30 minutes is diagnostic of adrenal insufficiency, with a standard test using 0.25 mg cosyntropin IV or IM 2, 3

Critical Clinical Context

• HPA axis suppression should be anticipated in any patient receiving more than 7.5 mg prednisolone equivalent daily for more than 3 weeks, with approximately 39-48% of patients on chronic low-dose prednisolone having adrenal insufficiency 1
• Even doses as low as 5 mg prednisolone daily for more than 1 month can cause adrenal suppression in a significant proportion of adults 2

Important Caveats and Pitfalls

• The Endocrine Society recommends never attempting diagnostic testing while the patient is actively taking prednisolone, as morning cortisol will be falsely low due to iatrogenic secondary adrenal insufficiency 3
• If a patient is acutely ill or unstable, immediately treat with IV hydrocortisone 100 mg without waiting for testing, as the 48-hour washout is only safe for stable outpatients 2, 4

Alternative Approach for Long-Term Steroid Users

• For patients on chronic prednisolone who cannot safely stop for 48 hours, consider empiric glucocorticoid replacement and defer definitive testing for 3 months after switching to physiologic hydrocortisone replacement 3
• After 3 months on stable hydrocortisone maintenance therapy, perform ACTH stimulation testing to assess HPA axis recovery, prioritizing patient safety over immediate diagnostic certainty 3, 5

Mortality Considerations

• Switching from prednisolone to hydrocortisone for chronic replacement reduces cumulative glucocorticoid exposure and associated complications, with a significant reduction in mortality 5